1. Introduction {#sec1-ijms-16-19602}
===============

Schizophrenia is a mental disorder that is characterized by abnormal social behavior and altered perception of reality. Several studies suggested that genetic background and environmental factors play an important role in the development of schizophrenia. Recently, there has also been increasing interest in the role of free oxidative stress in the pathogenesis of schizophrenia. Oxidative damage and neuronal inflammation can lead to the onset of schizophrenia \[[@B1-ijms-16-19602],[@B2-ijms-16-19602],[@B3-ijms-16-19602],[@B4-ijms-16-19602],[@B5-ijms-16-19602]\].

Glutathione *S*-transferases (GSTs) are a family of eukaryotic and prokaryotic phase II metabolic isozymes. GSTs are one of the key enzymes that regulate the conversion of toxic compounds to hydrophilic metabolites for the purpose of detoxification \[[@B6-ijms-16-19602],[@B7-ijms-16-19602]\]. In addition, they play an important role as neuro-protective antioxidants by protecting neural cells from oxidative stress \[[@B4-ijms-16-19602],[@B8-ijms-16-19602],[@B9-ijms-16-19602]\]. GSTs are expressed in many tissues in the human body. Some studies showed that GST levels of the cerebrospinal fluid were decreased in patients with schizophrenia \[[@B10-ijms-16-19602]\]. It suggested that GSTs may play a significant role in the development and progression of schizophrenia.

Human cytosolic GSTs belong to the alpha, zeta, theta, mu, pi, sigma, kappa, and omega classes and the main *GSTs* genes described as polymorphic in humans are glutathione *S*-transferase Mu1 (*GSTM1*), glutathione *S*-transferase T1 (*GSTT1*), and glutathione *S*-transferase P1 (*GSTP1*) \[[@B11-ijms-16-19602],[@B12-ijms-16-19602],[@B13-ijms-16-19602],[@B14-ijms-16-19602]\]. The *GSTM1* gene is located at 1p13.3, and the most common polymorphism in *GSTM1* is a deletion of the whole *GSTM1* gene with a lack of enzyme activity. The *GSTT1* gene is located at 22q11.2, and a homozygous deletion in *GSTT1* has also been reported. The *GSTP1* gene is located at 11q13, and the functional polymorphism at codon 105 in exon 5 of *GSTP1* has been found \[[@B11-ijms-16-19602],[@B12-ijms-16-19602],[@B13-ijms-16-19602],[@B14-ijms-16-19602]\]. These polymorphisms of *GSTM1*, *GSTT1*, and *GSTP1* have been investigated with various diseases including schizophrenia, hypertension, and capacity for oxidation and detoxification \[[@B15-ijms-16-19602],[@B16-ijms-16-19602]\]. Previous studies showed that *GSTM1* or *GSTT1* deletion polymorphisms were contributed to the loss of GST enzyme activities, respectively. So, combination in these *GSTM1* and *GSTT1* polymorphisms have been also investigated in order to find relationship with various diseases.

Up to now, a number of studies have evaluated the association between polymorphisms of *GSTs* gene and risk of schizophrenia in diverse populations. However, these results from the published studies remain conflicting rather than conclusive.

Therefore, we performed a meta-analysis on all eligible case-control studies to clarify the association between the *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms and risk of schizophrenia.

2. Results and Discussion {#sec2-ijms-16-19602}
=========================

2.1. Study Characteristics {#sec2dot1-ijms-16-19602}
--------------------------

The meta-analysis of this study was included 12 case and control studies. The characteristics from selected studies in *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms and schizophrenia are summarized in [Table 1](#ijms-16-19602-t001){ref-type="table"}. The 12 articles included 2742 schizophrenia patients and 2762 control subjects. The number of analyzed articles for *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms were nine, eight, and four articles, respectively \[[@B3-ijms-16-19602],[@B17-ijms-16-19602],[@B18-ijms-16-19602],[@B19-ijms-16-19602],[@B20-ijms-16-19602],[@B21-ijms-16-19602],[@B22-ijms-16-19602],[@B23-ijms-16-19602],[@B24-ijms-16-19602],[@B25-ijms-16-19602],[@B26-ijms-16-19602],[@B27-ijms-16-19602]\].

2.2. Quantitative Synthesis {#sec2dot2-ijms-16-19602}
---------------------------

The results of this heterogeneity test for meta-analysis are shown in [Table 2](#ijms-16-19602-t002){ref-type="table"}. The random-effects method was applied if the result of the Q test was *p* \< 0.05 or *I*^2^ statistic was \>50%. Otherwise, the fixed-effects method was adopted. For *GSTM1* polymorphism, nine studies containing 2156 schizophrenia patients and 2289 control subjects were included. *GSMT1* polymorphism did not show any significant association with schizophrenia (null type *vs*. present type, OR = 1.140, 95% CI = 0.893--1.455, *p* = 0.294 in [Table 2](#ijms-16-19602-t002){ref-type="table"} and [Figure 1](#ijms-16-19602-f001){ref-type="fig"}A). For *GSTT1* polymorphism, eight studies containing 1703 schizophrenia patients and 1726 control subjects were included. *GSTT1* polymorphism did not show any significant association with schizophrenia (null type *vs*. present type, OR = 0.777, 95% CI = 0.510--1.185, *p* = 0.241 in [Table 2](#ijms-16-19602-t002){ref-type="table"} and [Figure 1](#ijms-16-19602-f001){ref-type="fig"}B). Combination of *GSTM1* and *GSTT1* polymorphisms were analyzed using meta-analysis. Combination of Null type in *GSTM1* and *GSTT1* polymorphisms were compared with combination of other types in *GSTM1* and *GSTT1* polymorphisms between the schizophrenia group and the control group. Combinations of *GSTM1* and *GSTT1* polymorphisms were not associated with schizophrenia (OR = 1.241, 95% CI = 0.866--1.777, *p* = 0.240 in [Table 3](#ijms-16-19602-t003){ref-type="table"}).

For *GSTP1* polymorphism, four studies containing 659 schizophrenia patients and 562 control subjects were included. The genotype and allele of *GSTP1* were also not found to be associated with schizophrenia (codominant, dominant, recessive, and allele models, *p* \> 0.05, respectively in [Table 2](#ijms-16-19602-t002){ref-type="table"} and [Figure 1](#ijms-16-19602-f001){ref-type="fig"}C).

When stratified for ethnicity of East Asian, *GSTM1* polymorphism showed weak association with schizophrenia (OR = 1.314, 95% CI = 1.025--1.684, *p* = 0.031). However, there was no association between, *GSTT1* or *GSTP1* polymorphisms and schizophrenia (*p* \> 0.05 in [Table 2](#ijms-16-19602-t002){ref-type="table"} and [Table 3](#ijms-16-19602-t003){ref-type="table"}).

To identify publication bias in meta-analysis, we evaluated publication bias using Egger's regression. There was no publication bias (*p* \> 0.05).

ijms-16-19602-t001_Table 1

###### 

Information of eligible studies included in the meta-analysis.

  Authors                                                       Population   Schizophrenia/Control   Schizophrenia   Control                                                                        
  ------------------------------------------------------------- ------------ ----------------------- --------------- --------- ----- ------ ----- ----- ---- ------ ------ ----- ------ ----- ----- ----
  Harada *et al.* (2001) \[[@B17-ijms-16-19602]\]               Japanese     87/176                  57              30        ND    ND     ND    ND    ND   87     89     ND    ND     ND    ND    ND
  Pae *et al.* (2004) \[[@B18-ijms-16-19602]\]                  Korean       111/130                 70              41        ND    ND     ND    ND    ND   61     69     ND    ND     ND    ND    ND
  Matsuzawa *et al.* (2009) \[[@B19-ijms-16-19602]\]            Japanese     214/220                 129             85        88    127    154   55    5    119    101    80    140    162   54    4
  Rodríguez-Santiago *et al.* (2009) \[[@B20-ijms-16-19602]\]   Spanish      594/585                 243             351       142   452    ND    ND    ND   289    296    105   480    ND    ND    ND
  Watanabe *et al.* (2010) \[[@B21-ijms-16-19602]\]             Japanese     627/620                 336             291       ND    ND     ND    ND    ND   323    297    ND    ND     ND    ND    ND
  Gravina *et al.* (2011) \[[@B22-ijms-16-19602]\]              Italy        138/133                 82              56        25    113    66    50    8    70     63     30    103    65    48    9
  Kashani *et al.* (2012) \[[@B23-ijms-16-19602]\]              Iran         93/99                   15              78        6     87     48    37    8    26     73     2     97     64    27    8
  Kordi-Tamandani *et al.* (2014) \[[@B24-ijms-16-19602]\]      Iran         80/71                   ND              ND        16    64     ND    ND    ND   ND     ND     34    37     ND    ND    ND
  Pae *et al.* (2003) \[[@B3-ijms-16-19602]\]                   Korean       214/110                 ND              ND        ND    ND     139   68    7    ND     ND     ND    ND     74    33    3
  Raffa *et al.* (2013) \[[@B25-ijms-16-19602]\]                Tunisia      138/123                 79              59        59    79     ND    ND    ND   63     60     67    56     ND    ND    ND
  Saadat *et al.* (2007) \[[@B26-ijms-16-19602]\]               Iran         292/292                 ND              ND        52    240    ND    ND    ND   ND     ND     99    193    ND    ND    ND
  Saruwatari *et al.* (2013) \[[@B27-ijms-16-19602]\]           Japanese     154/203                 77              77        68    86     ND    ND    ND   99     104    99    104    ND    ND    ND
  Total                                                         \-           2742/2762               1091            1065      456   1248   407   210   28   1136   1153   516   1210   365   162   24

ND, no data; *GSTM1*, glutathione *S*-transferase mu 1; *GSTT1*, glutathione *S*-transferase theta 1; *GSTP1*, glutathione *S*-transferase pi 1.

ijms-16-19602-t002_Table 2

###### 

Overall analysis between polymorphisms of glutathione *S*-transferase genes (*GSTM1*, *GSTT1*, and *GSTP1*) and susceptibility of schizophrenia.

  Gene Symbols                      Comparsions                    Population   Heterogeneity   Model    OR             95% CI         *p*            
  --------------------------------- ------------------------------ ------------ --------------- -------- -------------- -------------- -------------- -------
  *GSTM1*                           Null type *vs.* Present type   All          0.001           70.969   Random         1.140          0.893--1.455   0.294
  East Asian                        0.090                          50.291       Random          1.314    1.025--1.684   0.031                         
  *GSTT1*                           Null type *vs.* Present type   All          \<0.001         83.745   Random         0.777          0.510--1.185   0.241
  East Asian                        0.194                          40.655       Fixed           1.020    0.767--1.355   0.893                         
  *GSTP1*                           Ile/Ile *vs.* Ile/Val          All          0.487           0.000    Fixed          1.167          0.905--1.504   0.235
  Ile/Ile *vs.* Val/Val             All                            0.939        0.000           Fixed    1.144          0.640--2.043   0.650          
  Ile/Ile *vs.* Ile/Val + Val/Val   All                            0.533        0.000           Fixed    1.163          0.911--1.484   0.227          
  Ile/Ile + Ile/Val *vs.* Val/Val   All                            0.889        0.000           Fixed    0.771          0.435--1.368   0.374          
  Ile *vs.* Val                     All                            0.666        0.000           Fixed    1.121          0.912--1.377   0.277          
  Ile/Ile *vs.* Ile/Val             East Asian                     0.945        0.000           Fixed    1.082          0.779--1.504   0.637          
  Ile/Ile *vs.* Val/Val             East Asian                     0.954        0.000           Fixed    1.279          0.490--3.339   0.615          
  Ile/Ile *vs.* Ile/Val + Val/Val   East Asian                     0.954        0.000           Fixed    1.907          0.797--1.510   0.569          
  Ile/Ile + Ile/Val *vs.* Val/Val   East Asian                     0.982        0.000           Fixed    0.956          0.367--2.490   0.927          
  Ile *vs.* Val                     East Asian                     0.979        0.000           Fixed    1.095          0.827--1.450   0.525          

OR, odds ratio; CI, confidence interval; *GSTM1*, glutathione *S*-transferase mu 1; *GSTT1*, glutathione *S*-transferase theta 1; *GSTP1*, glutathione *S*-transferase pi 1.

ijms-16-19602-t003_Table 3

###### 

Overall analysis between combination of glutathione *S*-transferase genes (*GSTM1* and *GSTT1*) and susceptibility of schizophrenia.

  Gene symbols    Combination                   Population   Heterogeneity   Model     OR      95% CI   *p*            
  --------------- ----------------------------- ------------ --------------- --------- ------- -------- -------------- -------
  *GSTM1-GSTT1*   Null type *vs.* other types   All          0.958           \<0.001   Fixed   1.241    0.866--1.777   0.240

OR, odds ratio; CI, confidence interval.

![Odds ratio and 95% CIs are presented for individual studies (black square and line) and meta-analysis results (diamond). (**A**) Analysis of null type *vs*. present type of *GSTM1* polymorphism; (**B**) Analysis of null type *vs*. present type of *GSTT1* polymorphism; (**C**) Analysis of Val allele *vs*. Ile allele of *GSTP1* polymorphism.](ijms-16-19602-g001){#ijms-16-19602-f001}

2.3. Discussion {#sec2dot3-ijms-16-19602}
---------------

Oxidative stress-mediated neuronal damage has been regarded as an important factor in the development of schizophrenia. We supposed that GSTs play an important role in antioxidant defenses by modulating various kinases, and we hypothesized that GSTs are related to the development of schizophrenia. \[[@B28-ijms-16-19602],[@B29-ijms-16-19602],[@B30-ijms-16-19602]\]. In the present study, we examined the association between the polymorphisms of *GSTM1*, *GSTT1*, and *GSTP1* and the schizophrenia risk. To the best of our knowledge, this is the first meta-analysis to investigate the association between these polymorphisms and the development of schizophrenia.

The correlations between *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms and the risk of schizophrenia have been investigated in a broad range of studies with either a relatively small or larger sample of the various populations. However, because of the differences in the number of participants and their genetic backgrounds, the evidence provided by each study is not sufficient to draw a convincing conclusion. We conducted a meta-analysis including with 2742 schizophrenia and 2762 controls from 12 case-control studies to evaluate the association between *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms and the development of schizophrenia.

In our study, there were no significant associations between *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms and risk of schizophrenia under any genetic model in the total population. Further subgroup analysis by ethnicity also demonstrated that only *GSTM1* polymorphism showed weak association with increased the risk of schizophrenia. We should also note the importance of heterogeneity. Heterogeneity was found in some comparisons in our meta-analysis. To get a more full and accurate detail of the precious data, we used the random-effects model. The results were stable with the sensitivity analysis, which did not change the results of the meta-analysis.

Some limitations remain in this meta-analysis and the results should be interpreted with caution. First, meta-analysis is a secondary and retrospective study type that is limited by the quality of primary studies. Second, we were unable to analyze gene-gene and gene-environment interactions.

This study investigated the relationship between *GSTM1*, *GSTT1*, and *GSTP1* polymorphisms and the development of schizophrenia. In conclusion, we found that *GSTM1* polymorphism was associated with susceptibility to schizophrenia in only East Asian population. Further larger studies considering gene-gene and gene-environment interactions are required to provide more precise evidence of the association between *GSTM1*, *GSTT1*, and *GSTP1* and the risk of schizophrenia.

3. Experimental Section {#sec3-ijms-16-19602}
=======================

3.1. Search Strategy {#sec3dot1-ijms-16-19602}
--------------------

Case and control studies were searched in PubMed, Google, Embase, and Korean databases (KISS, KMbase, and RISS) up to April 2015 without language restrictions. Relevant studies were identified using the terms: "glutathione-related enzyme" or "GSTM, or GSTT, or GSTP" and "polymorphism or polymorphisms" and "schizophrenia". Only human studies were selected. Additional studies were identified by hand search of original or review articles. If data or data subsets were published in more than one article, only the publication with the largest sample size was included.

3.2. Inclusion Criteria {#sec3dot2-ijms-16-19602}
-----------------------

Studies were included if they met the following criteria: (1) they evaluated the association between the *GSTM1*, *GSTT1*, or *GSTP1* polymorphisms and schizophrenia; (2) they used a case-control study design; (3) and they contained sufficient distribution of *GSTM1*, *GSTT1*, or *GSTP1* polymorphism in the schizophrenia group and the control group for the estimation of an odds ratio (OR) with a 95% confidence interval (CI).

3.3. Data Extraction {#sec3dot3-ijms-16-19602}
--------------------

The two investigators independently extracted data and formed an analysis. When they differed in their conclusions, they rechecked the data again and reached a consensus through discussion. Data extracted from the selected articles included the first author's name, year of publication, country of origin, ethnicity of the study population, number of cases and controls, and the genotype frequency of *GSTM1*, *GSTT1*, or *GSTP1* polymorphisms.

3.4. Statistical Analysis {#sec3dot4-ijms-16-19602}
-------------------------

Meta-analysis was performed using a comprehensive meta-analysis software program (Corporation, NJ, USA). The pooled *p* value, OR and 95% CI were used to investigate the association between risk of schizophrenia and *GSTM1*, *GSTT1*, or *GSTP1* polymorphisms. Firstly, we calculated the heterogeneity of studies. A χ^2^-test-based *Q* statistic test and *I*^2^ test were applied. The random-effects DerSimonian and Laird method was adopted if the result of the *Q* test was *p* \< 0.05 or *I*^2^ statistic was \>50%, which indicated a statistically significant degree of heterogeneity between the studies. Otherwise, the fixed-effects Mantel-Haenszel method was adopted. Publication bias was evaluated by Egger's regression.

For meta-analysis of *GSTM1* and *GSTT1* polymorphisms, the pooled ORs, 95% CI, and *p* value were calculated using null type versus (*vs*.) present type. And combination of *GSTM1* and *GSTT1* polymorphisms were also analyzed in meta-analysis \[[@B15-ijms-16-19602]\]. For *GSTP1*, the pooled ORs were calculated for codominant 1 model (Ile/Ile *vs*. Ile/Val), codominant 2 model (Ile/Ile *vs*. Val/Val), dominant model (Ile/Ile *vs*. Ile/Val + Val/Val), recessive model (Ile/Ile + Ile/Val *vs*. Val/Val) and allelic model (Ile *vs.* Val). Further subgroup analysis by ethnicity, the East Asian population only included Koreans and Japanese. The value of *p* \< 0.05 was regarded to indicate statistical significance.

4. Conclusions {#sec4-ijms-16-19602}
==============

*GSTM1* polymorphism was associated with susceptibility to schizophrenia in only East Asian population and *GSTT1* and *GSTP1* polymorphisms did not related to schizophrenia.
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